Efficacy and safety of dacomitinib in treatment-naive patients with advanced NSCLC harboring uncommon EGFR mutations

被引：0
|
作者：
Wu, L. [1 ]
Pu, X. [2 ]
Zhou, Y. [2 ]
Kong, Y. [2 ]
Chen, B. [2 ]
Yang, A. [3 ]
Li, J. [2 ]
Li, K. [2 ]
Xu, Y. [2 ]
机构：
[1] Hunan Canc Hosp, Thorac Med Oncol Dept, Changsha, Peoples R China
[2] Hunan Canc Hosp, Dept Thorac Oncol 2, Changsha, Peoples R China
[3] Hunan Canc Hosp, Dept Radiotherapy, Changsha, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.652
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
574P
引用
收藏
页码：S1695 / S1695
页数：1
相关论文
共 50 条
  • [31] Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations
    Bazhenova, Lyudmila
    Minchom, Anna
    Viteri, Santiago
    Bauml, Joshua M.
    Ou, Sai-Hong Ignatius
    Gadgeel, Shirish M.
    Manuel Trigo, Jose
    Backenroth, Daniel
    Li, Tracy
    Londhe, Anil
    Mahadevia, Parthiv
    Girard, Nicolas
    LUNG CANCER, 2021, 162 : 154 - 161
  • [32] EGFR mutations in patients with advanced NSCLC
    Fiala, Ondrej
    Pesek, Milos
    Finek, Jindrich
    Bruha, Frantisek
    Bortlicek, Zbynek
    Krejci, Jana
    Benesova, Lucie
    Minarik, Marek
    LUNG CANCER, 2012, 77 : S30 - S30
  • [33] Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients
    Wang, Chunsheng
    Zhao, Kewei
    Hu, Shanliang
    Dong, Wei
    Gong, Yan
    Li, Minghuan
    Xie, Conghua
    LUNG CANCER, 2022, 172 : 86 - 93
  • [34] A Phase II Study of Afatinib Treatment for Elderly Patients with Previously Untreated Advanced NSCLC Harboring EGFR Mutations
    Suzuki, K.
    Imai, H.
    Kaira, K.
    Anzai, M.
    Tsuda, T.
    Ishizuka, T.
    Kuwako, T.
    Naruse, I.
    Nemoto, K.
    Uchino, J.
    Morozumi, N.
    Ishihara, S.
    Minato, K.
    Hisada, T.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S498 - S498
  • [35] Efficacy and safety of poziotinib in treatment-naive NSCLC harboring HER2 exon 20 mutations: A multinational phase II study (ZENITH20-4)
    Cornelissen, R.
    Sun, S.
    Wollner, M.
    Garassino, M. C. C.
    Prelaj, A.
    Haura, E. B.
    Piotrowska, Z.
    Goldman, J. W.
    Socinski, M.
    Dreling, L.
    Bhat, G.
    Lebel, F.
    Le, X.
    ANNALS OF ONCOLOGY, 2021, 32 : S1324 - S1324
  • [36] Activity of afatinib in patients with NSCLC harboring novel uncommon EGFR mutations with or without co-mutations: a case report
    Christopoulos, Petros
    Herster, Franziska
    Hoffknecht, Petra
    Falk, Markus
    Tiemann, Markus
    Kopp, Hans-Georg
    Althoff, Andre
    Stammberger, Anja
    Laack, Eckart
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [37] Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis
    Tan, Daniel S. W.
    Geater, Sarayut
    Yu, Chong-Jen
    Tsai, Chun -Ming
    Hsia, Te-Chun
    Chen, Jun
    Lin, Meng-Chih
    Lu, You
    Sriuranpong, Virote
    Yang, Cheng-Ta
    Sen, Paramita
    Branle, Fabrice
    Shi, Michael
    Wu, Yi-Long
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (03):
  • [38] Safety and Efficacy of Fingolimod in Treatment-Naive Multiple Sclerosis Patients
    Marriott, James J.
    JOURNAL OF CENTRAL NERVOUS SYSTEM DISEASE, 2011, 3 : 43 - 50
  • [39] Efficacy of dacomitinib in patients with EGFR-mutated NSCLC and brain metastases
    Zhang, Jinyao
    Wang, Yan
    Liu, Ziling
    Wang, Lin
    Yao, Yu
    Liu, Yutao
    Hao, Xue Zhi
    Wang, Jianyang
    Xing, Puyuan
    Li, Junling
    THORACIC CANCER, 2021, 12 (24) : 3407 - 3415
  • [40] Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naive Patients with Advanced Lung Adenocarcinoma
    Park, Jangchul
    Kobayashi, Yoshihisa
    Urayama, Kevin Y.
    Yamaura, Hidekazu
    Yatabe, Yasushi
    Hida, Toyoaki
    PLOS ONE, 2016, 11 (08):
12345